Parameter
| Biomarker | Triglyceride (TG) | Full name | Triglyceride | Molecular Type | Lipids (triglycerides) |
|---|---|---|---|---|---|
| Molecular Formula | C₃H₅(OOC-R)₃ (R = fatty acid chain, e.g., palmitic acid: C₁₆H₃₂O₂) | Molecular Weight | Varies by fatty acid chain (e.g., triolein: ~885 Da) | Core Functional Dimensions | Energy storage, lipoprotein transport |
| Disease | Metabolic Associated Fatty Liver Disease (MASLD) | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Plasma (lipid detection, lipidomics mass spectrometry), liver tissue (lipidomics mass spectrometry) | ||
| Pathobiological Mechanisms | De novo synthesis and peripheral fat mobilization in the liver are increased, and the proportion of specific VLDL-TG species is high, which promotes liver fat accumulation | ||||
| Clinical Availability Status | Plasma (lipid detection, lipidomics mass spectrometry), liver tissue (lipidomics mass spectrometry) | ||||
| Notes and Dynamics | Clinical routine test indicators, TG lowering drugs can improve liver fat, but long-term monitoring is needed | ||||